InterVenn Biosciences has developed a proprietary glycoproteomic platform based on AI and mass spectrometry for the discovery of novel glycoproteomic biomarkers and their application to next-gen precision medicine.
The company is working to find new solutions in a range of oncology indications, along with making its Vista suite of solutions available to its partners for advanced life-science R&D applications.
InterVenn’s VISTATM is the first commercially available platform that can assess (serum or plasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides.
Top 25 women biotech leaders of 2022, per Healthcare Technology Report
Erwin Estigarribia is Appointed President and Chief Operating Officer of InterVenn Biosciences
InterVenn Shifts Direction Again, From Immunotherapy Focus to Cancer Screening
InterVenn Biosciences Co-Founder Carolyn Bertozzi Awarded Nobel Prize in Chemistry
Nobel Prize Awarded to Three Scientists for Development of Click Chemistry